Recently research has shown that Visugromab, a GDF15 neutralizing antibody, can improve efficacy of anti-PD-1-based cancer immunotherapy in non-squamous non-small cell lung cancer, urothelial cancer, and potentially HCC, highlighting its clinical relevance (38). Here, GDF15 is linked to non-small cell squamous lung carcinoma.